Primary Job Title Co-Founder Primary Organization Opus Genetics(formerly Ocuphire Pharma)
Location Farmington Hills, Michigan, United States Regions Greater Detroit Area, Great Lakes, Midwestern US Gender Male
LinkedIn View on LinkedIn
Alan R. Meyer is a co-founder of Ocuphire and has served as Chief Operating Officer and expert advisor through 2019. Mr. Meyer was also a co-founder and Chief Executive Officer of Ocularis Pharma, where Nyxol eye drops were first developed, from 2002 to 2018, From 1992 to 2000, Mr. Meyer was the Executive Vice President, Chief Financial Officer,
and a member of the board of PathoGenesis. During his tenure, PathoGenesis developed and commercialized the world’s first aerosolized antibiotic, TOBI®. PathoGenesis went public in 1995 and was sold to Chiron Corporation in 2000 for $730 million. Prior to PathoGenesis, he served as CFO of several development-stage companies in healthcare, held positions of increasing responsibility in corporate finance and corporate development at Baxter Healthcare Corporation, and worked as a consultant for Arthur Andersen & Co. He has a B.S. in Engineering from the University of Illinois at Chicago, where he was a James Scholar and graduated with Highest Honors, and an M.B.A. from the Kellogg School of Management at Northwestern University, where he was an Austin Scholar.
